In large part the “price” they can charge will be the billing rates dictated by medicaid/care and insurance companies. That price will need to be lower than hedge fund owned biotech companies that seem to be driving the price gouging. Those parties aren’t going to agree to cover any drug that’s more expensive. But what a lot of them increasingly do is require cheaper generics in some way. Whether only covering generics or charging a much higher copay for name brand. Or even requiring you to get scrips from a mail order source.
That means competition. Which can only create downward pressure. Remember a hell of a lot of the drugs that are going up in price are out of patent. And the price drive is coming from the fact that only one company in the market is still manufacturing them.
